title: Cyclosporin A and sanglifehrin A enhance chemotherapeutic effect of cisplatin in C6 glioma cells.
abstract: Glioma is the most common type of brain tumors in adults, and treatment of high-grade gliomas is still palliative. Studies to date have revealed only modest effect in attenuating growth of these tumors with single agent therapy, but combination treatment appears to be more effective. Cyclophilin A (CypA), a target of immunosuppressive drugs cyclosporin A (CsA) and sanglifehrin A (SFA), is an intracellular protein that has peptidyl-prolyl cis-trans isomerase (PPIase) enzymatic activity. Previously, we showed that overexpressed CypA induced chemoresistance in cancer cells. Here we provide evidence that combination of cisplatin with either CsA or SFA synergistically enhances apoptotic cell death in C6 glioma cells, compared with single agent treatment. Enhanced apoptotic cell death is a result of an increase in ROS generation and a decrease in intracellular glutathione levels. Consistently, CypA knockdown by siRNA also enhances cisplatin-induced apoptosis. Immunohistochemical analysis showed increased expression of CypA in human glioblastoma multiforme, but not in normal human astrocytes. CypA was also shown to be up-regulated in C6 glioma cells during hypoxia. In conclusion, CsA or SFA in combination with cisplatin synergistically enhances cisplatin-induced apoptosis in C6 glioma cells via inhibition of PPIase activity of CypA, indicating that development of new drugs that selectively inhibit the CypA PPIase activity without immune suppression may facilitate alleviation of chemoresistance in treatment of high-grade glioma.
authors.affiliation: Department of Neurosurgery, The First Hospital of Jilin University, Changchun 130-021, PR China.
authors.forename: Xuezhe
authors.initials: X
authors.lastname: Han
authors.forename: Sung H
authors.initials: SH
authors.lastname: Yoon
authors.forename: Yan
authors.initials: Y
authors.lastname: Ding
authors.forename: Tae G
authors.initials: TG
authors.lastname: Choi
authors.forename: Won J
authors.initials: WJ
authors.lastname: Choi
authors.forename: Yun H
authors.initials: YH
authors.lastname: Kim
authors.forename: Young-Joo
authors.initials: YJ
authors.lastname: Kim
authors.forename: Young-Buhm
authors.initials: YB
authors.lastname: Huh
authors.forename: Joohun
authors.initials: J
authors.lastname: Ha
authors.forename: Sung S
authors.initials: SS
authors.lastname: Kim
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000188:drug therapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002945:Cisplatin / Q000494:pharmacology; D021984:Cyclophilin A / Q000037:antagonists & inhibitors; D016572:Cyclosporine / Q000494:pharmacology*; D004357:Drug Synergism; D005910:Glioma / Q000188:drug therapy*; D006801:Humans; D007150:Immunohistochemistry; D007783:Lactones / Q000494:pharmacology; D034741:RNA, Small Interfering; D051381:Rats; D017382:Reactive Oxygen Species / Q000378:metabolism; D013141:Spiro Compounds / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D007783:Lactones; D034741:RNA, Small Interfering; D017382:Reactive Oxygen Species; D013141:Spiro Compounds; C121329:sanglifehrin A; D016572:Cyclosporine; D021984:Cyclophilin A; D002945:Cisplatin